[PDF] Top 20 Biosimilars: potential implications for clinicians

... of biosimilars are far more than those for generic chemical drugs, which have predictable character- ...contrast, biosimilars require meticulous comparison with the refer- ence biologic, which involves a ... See full document

... the potential for a share in the large and growing market in biolog- ics, has led to an interest in develop- ing drugs that are biologically similar to products already approved by the ...has implications ... See full document

... are potential concerns regarding the use of biosimilars in Cancer patients that warrant consideration when making a biopharmaceutical product ...choice. Clinicians need to have a thorough ... See full document

... prospective biosimilars are needed in Iraq. The approval of biosimilars in Iraq should be the responsibility of an expert committee of scientists and clinicians that reviews all evidence of ... See full document

... Distributor reputation and capabilities The companies that dominate the U.S. and global insulin markets have established reputations and are trusted by clinicians, patients, payors, and regulators. They ... See full document

... of biosimilars with the innovator product, clinicians and health care workers should be made aware of some of the issues that have emerged during the development and approval of these ...of ... See full document

... exposures for the prevalence of impacts on OHRQoL. Previously detected confounding variables (age, dental caries and malocclusion) (24) were included in the multivariable models in order to examine the independent ... See full document

... have implications for the care of patients in primary care or other generalist ...their implications for generalist ...for potential articles of ...a potential impact on generalist ...with ... See full document

... of potential marketing authorization and reimbursement of additional pregabalins in the Czech Republic, in addition to Pfizer’s own generic pregabalin, will also be monitored given current uncertainties (Table ... See full document

... the potential of biosimilars ...for biosimilars among European countries including national frameworks ...regarding biosimilars has been included in treatment guidelines for any of the cancer ... See full document

... example, while open tendering may increase the number of potential suppliers, complications and delays can often occur post-qualification. The success of open tenders post- qualification depends on the capacity of ... See full document

... the potential to induce an immune ...immunogenic potential, several factors are known to affect a product’s immunogenic ...antigenic potential of a biopharmaceutical, but cannot predict its ... See full document

... ago for an erythropoietin product where a post-approval formulation change led to an increased number of cases of pure red cell aplasia (PRCA) this complication was manifested by severe epoetin-resistant anemia which ... See full document

... Biosimilar developers must demonstrate that their bio- similar is highly similar to the bio-originator (notwith- standing normal variability inherent to all biologics) and that there are no clinically meaningful ... See full document

... that clinicians believed it beneficial for the application to be a hub for evidence-based information specifically for educational purposes and using ‘patient-friendly’ language and visuals, include or track ... See full document

... booming biosimilars market. However, as the field of biosimilars develops, challenges in immunogenicity studies, securing market share, exclusivity and regulations still ...between biosimilars and ... See full document

... Practical Implications Considering that up to 72% of college students have been found to report experiencing bullying at some point in their primary, secondary, or college school years (Chapell, 2006), it is ... See full document

... three biosimilars evaluated are Inflectra®, Basaglar®, and Grastofil®, and the three originator biologics are Remicade®, Lantus® and ...and potential cost savings were obtained from IQVIA™, a multi-national ... See full document

... tions, clinicians’ become more aware of others’ expertise (the knowledge recognition process described in transactive memory systems ...other clinicians and the local experts fa- cilitate regular access to ... See full document

... Though similar biologics are not new drug products and their risk will be similar to reference biologic; however as similar biologics are authorized based on a reduced preclinical and clinical data package, it is ... See full document